Veristat to Acquire Certara Regulatory and Medical Writing Business
April 22, 2026
Veristat announced it has entered into a definitive agreement to acquire Certara’s Regulatory and Medical Writing business. The deal is expected to close in Q2 2026 and will add 200+ (approximately 220) medical writing and regulatory experts to expand Veristat’s regulatory writing, submission strategy, and advisory capabilities across the drug development lifecycle.
- Targets
- Certara's Regulatory and Medical Writing business
- Sellers
- Certara, Inc.
- Industry
- Healthcare Services
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
TransPerfect Acquires Synterex to Expand Medical Writing Expertise and AI-Enabled Regulatory Solutions
October 1, 2026
Healthcare Services
TransPerfect announced it has acquired Synterex, a Dedham, Massachusetts-based clinical and regulatory writing and technology-enabled consulting firm serving biotech and pharmaceutical clients. Synterex’s AgileWriter.ai platform supports AI-assisted authoring and regulatory content workflows, which TransPerfect says will integrate into its Life Sciences offerings as a division.
-
Veristat Acquires Instat Clinical Research
October 19, 2023
Healthcare Services
Veristat, a full-service clinical research organization, has acquired Instat Clinical Research, a biometrics-focused CRO with teams in the United States and India. The deal expands Veristat's biometrics, data management, biostatistics, and statistical programming capabilities while adding offshore capacity to enable round-the-clock support for clinical studies.
-
Certara Acquires Vyasa Analytics
January 4, 2023
AI & Machine Learning
Certara, Inc. (Nasdaq: CERT) has acquired Vyasa Analytics, LLC to integrate Vyasa’s deep-learning platform LAYAR and AI capabilities into Certara’s biosimulation software suite. The acquisition expands Certara’s data fabric and AI-driven prediction capabilities to accelerate drug discovery and development.
-
Certara Acquires Pinnacle 21
October 4, 2021
Software
Certara, Inc. completed the acquisition of Pinnacle 21, a provider of SaaS solutions for clinical data standardization, validation and regulatory-submission readiness. Equity holders of Pinnacle 21 received approximately $250 million in cash and 2,239,717 restricted shares of Certara common stock; Certara said the deal expands its data-sciences and software capabilities and is expected to be accretive to revenue and adjusted EBITDA.
-
WindRose Health Investors Recapitalizes Veristat Group Inc.
April 7, 2021
Healthcare Services
WindRose Health Investors completed an equity recapitalization of Veristat Group Inc., a global clinical research organization, with Veristat management retaining a significant minority stake. The investment will provide capital and strategic resources to support Veristat's growth and expansion across clinical development, regulatory affairs, biostatistics, data management and pharmacovigilance; terms were not disclosed.
-
Veristat Acquires The Clinical Trial Company Ltd (TCTC Group)
January 6, 2020
Healthcare Services
Veristat, a full-service CRO based in Southborough, Massachusetts, has acquired The Clinical Trial Company Ltd (TCTC Group), a Europe-headquartered contract research organization. The deal expands Veristat's European footprint and adds TCTC's expertise in gene and cell therapy, CNS and orphan disease clinical trials to Veristat's service offering.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.